Evasion of Type I Interferon by SARS-CoV-2

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication and host immune response determine coronavirus disease 2019 (COVID-19), but studies evaluating viral evasion of immune response are lacking. Here, we use unbiased screening to identify SARS-CoV-2 proteins that antagonize type I interferon (IFN-I) response. We found three proteins that antagonize IFN-I production via distinct mechanisms: nonstructural protein 6 (nsp6) binds TANK binding kinase 1 (TBK1) to suppress interferon regulatory factor 3 (IRF3) phosphorylation, nsp13 binds and blocks TBK1 phosphorylation, and open reading frame 6 (ORF6) binds importin Karyopherin α 2 (KPNA2) to inhibit IRF3 nuclear translocation. We identify two sets of viral proteins that antagonize IFN-I signaling through blocking signal transducer and activator of transcription 1 (STAT1)/STAT2 phosphorylation or nuclear translocation. Remarkably, SARS-CoV-2 nsp1 and nsp6 suppress IFN-I signaling more efficiently than SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Thus, when treated with IFN-I, a SARS-CoV-2 replicon replicates to a higher level than chimeric replicons containing nsp1 or nsp6 from SARS-CoV or MERS-CoV. Altogether, the study provides insights on SARS-CoV-2 evasion of IFN-I response and its potential impact on viral transmission and pathogenesis.

Cited by papers we hold 25

• Nuclear transport proteins: structure, function and disease relevance · 2023
  No notice
• Ribosome biogenesis in disease: new players and therapeutic targets · 2023
  No notice
• Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway · 2022
  Not checked
• Interaction of HDAC2 with SARS-CoV-2 NSP5 and IRF3 Is Not Required for NSP5-Mediated Inhibition of Type I Interferon Signaling Pathway · 2022
  Not checked
• Structural biology of SARS-CoV-2: open the door for novel therapies · 2022
  No notice
• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
  No notice
• SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB · 2022
  No notice
• SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity · 2022
  No notice
• SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1 · 2021
  No notice
• SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns · 2021
  No notice
• SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis · 2021
  No notice
• SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98 · 2021
  No notice
• Emerging SARS-CoV-2 variants of concern and potential intervention approaches · 2021
  No notice
• SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation · 2021
  No notice
• SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation · 2021
  No notice
• SARS-CoV-2 one year on: evidence for ongoing viral adaptation · 2021
  No notice
• Innate immune sensing of coronavirus and viral evasion strategies · 2021
  No notice
• The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 · 2021
  No notice
• SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon · 2021
  Corrected

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.